Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions
November 12, 2018 06:55 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
Approximately 98% of patients receiving highest dose achieved reductions in Lp(a) levels below the established threshold of risk for CVD events Favorable safety and tolerability profile observed in...
Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions
November 08, 2018 07:00 ET
|
Akcea Therapeutics, Inc.
Results to be presented show a significant reduction of Lp(a) levels, favorable safety and tolerability profile BOSTON and CARLSBAD, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics,...
Akcea Therapeutics to Present at Upcoming Investor Conferences
November 06, 2018 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with...
Akcea Reports Financial Results and Highlights for Third Quarter 2018
November 05, 2018 16:05 ET
|
Akcea Therapeutics, Inc.
TEGSEDITM (inotersen) Approved in United States, European Union & Canada $320 million to fund the company through key milestones Conference Call Webcast Monday,...
Akcea reconoce el primer Día mundial de concientización sobre el Síndrome de Quilomicronemia Familiar (FCS)
November 02, 2018 12:46 ET
|
Akcea Therapeutics, Inc.
La comunidad se enfoca en aumentar el conocimiento con respecto a la carga que representa el FCS y el impacto que tiene en la vida diaria BOSTON, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Akcea...
Akcea Riconosce la Prima Giornata Mondiale di Sensibilizzazione sulla Sindrome da Chilomicronemia Familiare (FCS)
November 02, 2018 12:46 ET
|
Akcea Therapeutics, Inc.
La comunità si impegna a promuovere la consapevolezza in merito alla FCS e al suo oneroso impatto sulla vita quotidiana BOSTON, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:...
Akcea begeht den ersten weltweiten Tag des familiären Chylomikronämie-Syndroms (FCS)
November 02, 2018 12:46 ET
|
Akcea Therapeutics, Inc.
Die Gemeinschaft konzentriert sich auf die Sensibilisierung für die Belastung durch FCS und die Auswirkungen auf das tägliche Leben BOSTON, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics,...
Akcea célèbre la première journée mondiale de sensibilisation au syndrome de chylomicronémie familiale (FCS)
November 02, 2018 12:46 ET
|
Akcea Therapeutics, Inc.
La communauté se concentre sur la sensibilisation au fardeau du FCS et à son impact sur la vie quotidienne BOSTON, 02 nov. 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ : AKCA), une...
Akcea erkent eerste Werelddag voor familiaal chylomicronemiesyndroom (FCS)
November 02, 2018 12:46 ET
|
Akcea Therapeutics, Inc.
FCS-gemeenschap focust op de bewustmaking van de problemen die FCS met zich meebrengt en de impact ervan op het dagelijkse leven BOSTON, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc....
Akcea Recognizes First Global Familial Chylomicronemia Syndrome (FCS) Awareness Day
November 02, 2018 07:00 ET
|
Akcea Therapeutics, Inc.
Community focuses on elevating awareness of the burden of FCS and impact on daily living BOSTON, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis...